Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Multiple Myeloma 4Hematologic Neoplasms 4Carcinoma, Renal Cell 4Breast Neoplasms 4Prostatic Neoplasms 3Neuroendocrine Tumors 3Urothelial Cancer 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Stomach Neoplasms 1

Interventions

nilotinib 1bosutinib 1asciminib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Philadelphia Chromosome × 30 days × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡